New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTTPH, SLB, PFE, LVS, FNP, BLK, UIS, TDG, SI, OHI, KIM, LLY, EV, BHI, PSUN, MXIM, JNJ, LNG, ATI, BMRN, BPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Allegheny Technologies (ATI) downgraded to Hold from Buy at Deutsche Bank... BP (BP) downgraded to Neutral from Outperform at Exane BNP Paribas... BioMarin (BMRN) downgraded to Equal Weight from Overweight at Barclays... BlackRock (BLK) downgraded to Neutral from Buy at Goldman... Cheniere Energy (LNG) downgraded to Neutral from Buy at Citigroup... Eli Lilly (LLY) downgraded to Underweight from Equal Weight at Barclays... Fifth & Pacific (FNP) downgraded to Hold from Buy at Brean Capital... Johnson & Johnson (JNJ) downgraded to Equal Weight from Overweight at Barclays... Kimco Realty (KIM) downgraded to Sell from Neutral at UBS... Las Vegas Sands (LVS) downgraded to Market Perform from Outperform at FBR Capital... Maxim Integrated (MXIM) downgraded to Perform from Outperform at Oppenheimer... Omega Healthcare (OHI) downgraded to Sell from Neutral at UBS... Pacific Sunwear (PSUN) downgraded to Neutral from Buy at Janney Capital... Pfizer (PFE) downgraded to Market Perform from Outperform at Cowen... Siemens (SI) downgraded to Neutral from Buy at BofA/Merrill... Schlumberger (SLB) downgraded to Sector Perform from Outperform at Iberia... Baker Hughes (BHI) downgraded to Sector Perform from Outperform at Iberia... TransDigm (TDG) downgraded to Neutral from Buy at DA Davidson... TRI Pointe Homes (TPH) downgraded to Market Perform from Outperform at FBR Capital... Eaton Vance (EV) downgraded at Susquehanna... Unisys (UIS) downgraded to Neutral from Positive at Susquehanna.
News For ATI;BP;BMRN;BLK;LNG;LLY;FNP;JNJ;KIM;LVS;MXIM;OHI;PFE;PSUN;SI;SLB;BHI;TDG;TPH;EV;UIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
August 20, 2015
07:37 EDTLLYEli Lilly's Jardiance for diabetes meets primary endpoint in clinical trial
Subscribe for More Information
07:21 EDTEVEaton Vance upgraded to Neutral from Sell at Citi
Subscribe for More Information
06:10 EDTBPAuction for drilling leases attracts little interest, NY Times reports
A federal auction for drilling leases in the Gulf of Mexico Wednesday attracted only $22.7M in sales from five companies, the lowest since 1986, reports the New York Times. Most companies have insisted they would not sacrifice production in future years, but executives have recently expressed concern that the oil price collapse could last through 2016 and possibly even 2017. Publicly traded companies in the space include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
August 19, 2015
16:06 EDTBMRNBioMarin receives rare pediatric disease designation from FDA for drisapersen
Subscribe for More Information
09:17 EDTBMRN'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:48 EDTEVEaton Vance reports Q3 AUM up 8% YoY to $312.6B
08:46 EDTEVEaton Vance reports Q3 adjusted EPS 57c, consensus 62c
Reports Q3 revenue $355.5M, consensus $364.53M.
08:29 EDTBMRNFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
07:38 EDTLNGEnerCom to hold a conference
Subscribe for More Information
07:33 EDTSLBCameron and Schlumberger's Subsea to supply pump system for Stones development
Subscribe for More Information
07:22 EDTLNGCitigroup to hold a conference
Subscribe for More Information
06:13 EDTBLKSnapdeal secures $500M in investment round led by Alibaba, Softbank
Subscribe for More Information
August 18, 2015
18:30 EDTMXIMChip makers advance after Analog Devices reports Q3 financial results
Subscribe for More Information
10:01 EDTLLYEli Lilly says Humalog 200 units/mL KwikPen available in U.S. pharmacies
Subscribe for More Information
09:05 EDTMXIMMaxim Integrated management to meet with Evercore ISI
Meetings to be held in Minneapolis/Milwaukee/Chicago August 24-25 hosted by Evercore ISI.
07:29 EDTLNGEnerCom to hold a conference
The Oil & Gas Conference is being held in Denver, Colorado on August 16-20 with webcasted company presentations to begin on August 18 at 10:00 am; not all company presentations may be webcasted. Webcast Link
07:13 EDTLVSMacau GGR poised to sink 37% in August, says Bernstein
Subscribe for More Information
August 17, 2015
10:03 EDTBPEmerson signs 10-year agreement with BP for enhanced oil and gas execution
BP (BP) and Emerson (EMR) have signed a global agreement for Emerson Process Management, a global business of Emerson, to provide automation technologies and aftercare services for BP's upstream oil and gas operations. The new 10-year agreement extends the existing arrangement between the companies, allowing Emerson to provide an expanded scope of technologies and expertise that help ensure safe and competitive projects and support BP's Field of the Future program for enhanced operating efficiency and oil recovery. The new agreement expands the companies' existing relationship on upstream projects. Under the scope of the new agreement, Emerson will continue to supply automation system technologies, including distributed control systems and safety instrumented systems, but will now also provide valves and measurement instruments as well as technologies for supervisory control and data acquisition, asset management, and machinery health monitoring.
08:04 EDTSLBAccenture to acquire Schlumberger Business Consulting
Subscribe for More Information
06:45 EDTBPBP investors not sold on takeover talks, FT reports
Few BP investors have enough faith to buy into takeover talk given the company's own aggressive cost-cutting campaign might have eliminated the synergy upside to a potential purchaser, the Financial Times reports. Reference Link
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use